LXRX

Lexicon Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website lexpharma.com
Employees(FY) 135
ISIN US5288723027

Performance

+34.95%

+97.93%

-28.11%

-61.78%

-6.84%

YTD

-55.9%

Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Advanced Technical Analysis

Technical Analysis of LXRX 2025-04-28

The stock exhibits a mixed sentiment with a strong Moving Average Score of 75 indicating bullish momentum, while the Oscillators Score of 41 suggests a neutral to bearish outlook, and a Technical Score of 58 reflects a neutral stance overall. This combination implies that while there is some bullish strength, caution is warranted due to the weak...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LXRX

Stock Rank

Recent News & Updates

2025-04-01 20:00
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference(Globenewswire)
2025-03-28 06:10
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)(Seekingalpha)
2025-03-28 01:04
Novo Nordisk strikes $1bn deal for Lexicons oral obesity drug(Yahoo Finance)
2025-03-27 22:09
Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1(Yahoo Finance)
2025-03-27 19:30
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851(Globenewswire)
2025-03-06 19:30
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025(Globenewswire)
2025-03-06 13:17
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...(Yahoo Finance)
2025-03-06 04:10
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates(Yahoo Finance)
2025-03-06 03:18
Lexicon: Q4 Earnings Snapshot(Yahoo Finance)
2025-03-06 03:00
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates(Globenewswire)
2025-03-04 03:15
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025(Globenewswire)
2025-03-02 18:00
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain(Globenewswire)
2025-03-02 03:13
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain(Globenewswire)
2025-02-17 19:00
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)(Globenewswire)
2025-01-20 19:00
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain(Globenewswire)
2025-01-05 20:16
Heres Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10(Yahoo Finance)
2025-01-01 19:00
Lexicon Appoints Scott Coiante as Chief Financial Officer(Globenewswire)
2024-12-20 03:30
Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin)(Globenewswire)
2024-11-26 18:30
Lexicon completes subject enrolment for DPNP trial of LX9211(Yahoo Finance)
2024-11-25 19:00
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)(Globenewswire)
2024-11-25 03:15
Lexicon Pharmaceuticals to Participate in December Investor Conferences(Globenewswire)
2024-11-21 18:32
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA(Globenewswire)
2024-11-21 16:05
Lexicon to disband sales team, lay off 60% of staff(Yahoo Finance)
2024-11-20 03:05
Lexicon Appoints Ivan H. Cheung to Board of Directors(Globenewswire)
2024-11-13 19:00
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago(Globenewswire)
2024-11-12 13:20
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...(Yahoo Finance)
2024-11-12 04:25
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates(Yahoo Finance)
2024-11-12 03:25
Lexicon: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-12 03:05
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-10 18:15
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.